{"page":{"totalFilteredElements":71},"studies":[{"active":true,"description":"A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the \nEfficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab \nVedotin Plus R-CHP in Treatment-na&#239;ve Participants With GCB Subtype of Diffuse Large \nB-cell Lymphoma (DLBCL)","eudractNumber":"2024-515526-89","id":11240,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-07-03T11:19:15+02:00","shortTitle":"MK2140-011","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Klinische Pr&#252;fung der Phase III von CPX-351 zur Behandlung von Kindern mit Myeloischer Leuk&#228;mie mit Down-Syndrom 2018","eudractNumber":"2018-002988-25","id":8960,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-02-22T12:45:46+01:00","shortTitle":"ML-DS 2018","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>Constructing and validation of a robust, affordable, and widely applicable real-world outcome predictor for risk-tailored therapy for DLBCL patients in the German healthcare system</div>","eudractNumber":null,"id":11186,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06526065","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-02-13T10:15:01+01:00","shortTitle":"MMML-Predict","therapeutical":false,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC \nand Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and \nLenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in \nParticipants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended \nfor Autologous Stem Cell Transplant as Initial Therapy&#160;","eudractNumber":"2022-000909-28","id":9487,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05552222","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-06-01T12:39:06+02:00","shortTitle":"MajesTEC-7, 64007957MMY3005","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focos on digital side effect management","eudractNumber":"2021-000287-30","id":8045,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"}],"nctNumber":"NCT05362760","phase":{"id":"ph_11","name":"Phase IV"},"recruitmentStart":"2022-12-01T15:29:48+01:00","shortTitle":"Minerva","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<u>Na</u>tional acute <u>p</u>r<u>o</u>myelocytic <u>le</u>ukemia (APL) observational study NAPOLEON&#8208;Register der Deutschen AML Intergroup<br />","eudractNumber":null,"id":1351,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[{"name":"Others","id":"mt_8"},{"name":"Translokation","id":"mt_244"},{"name":"t(15;17)","id":"mt_179"},{"name":"Fusion Transcript of PML/RARa","id":"mt_269"}],"nctNumber":"NCT02192619","phase":null,"recruitmentStart":"2014-07-21T10:18:12+02:00","shortTitle":"NAPOLEON-Register","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Prospective multicenter registry for neonates, infants, children, adolescents, and adults with neuroblastic tumours.<br />","eudractNumber":null,"id":3381,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2017-01-01T09:29:18+01:00","shortTitle":"NB Registry 2016","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<p class=\"MsoNormal\">A Phase 2, Open-Label, Parallel Cohort Study of\nSubcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or\nMetastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer [CR109264]</p>","eudractNumber":"2022-000526-21","id":8484,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"EGFR","id":"mt_1"}],"nctNumber":"NCT05498428","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-03-01T11:55:23+01:00","shortTitle":"PALOMA-2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Pr&#228;vention von fr&#252;hen Darmkrebserkrankungen - PEARL","eudractNumber":null,"id":11520,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05541601","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-10-10T08:31:53+02:00","shortTitle":"PEARL","therapeutical":false,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A randomized phase II study to evaluate the safety and efficacy of trastuzumab deruxtecan versus CDK4/6 inhibitor based endocrine therapy as first line therapy of HR-positive and HER2-low/ultralow advanced breast cancer patients classified as non-luminal subtype according to gene expression profiling","eudractNumber":"2024-512360-55-00","id":12010,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-low","id":"mt_286"}],"nctNumber":"NCT06486883","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":null,"shortTitle":"PONTIAC","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"}]}]}